Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,288 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Mandibular Fractures
Interventions
Implants
Procedure
Lead sponsor
AO Clinical Investigation and Publishing Documentation
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
New York, New York • San Antonio, Texas
Conditions
Healthy Volunteer, Pharmacokinetics After Oral Intake
Interventions
ARN-75039
Drug
Lead sponsor
Arisan Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Secaucus, New Jersey
Conditions
Peanut Allergy
Interventions
Whole peanut extract, Placebo formulation
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
6 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more
Conditions
Percutaneous Coronary Intervention, Coronary Artery Disease (CAD), Angioplasty
Interventions
PMX-60056
Drug
Lead sponsor
PolyMedix, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
South Bend, Indiana • Detroit, Michigan • Rapid City, South Dakota
Conditions
Critical Illness, Depressive Symptoms
Interventions
Ketamine (0.5 mg/kg), Normal Saline (0.9% NaCl)
Drug · Other
Lead sponsor
Hospital Italiano de Buenos Aires
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more
Conditions
Refractive Error, Myopia
Interventions
Verofilcon A contact lenses, Somofilcon A contact lenses
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
8
States / cities
Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 5 more
Conditions
Shigellosis
Interventions
Shigella 4V, MenACWY, Rabies, Diphtheria, Tetanus and Pertussis (DTaP), Placebo
Biological
Lead sponsor
LimmaTech Biologics AG
Industry
Eligibility
8 Months to 50 Years
Enrollment
597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
0
States / cities
Not listed
Conditions
Colorectal Neoplasms, Diarrhea
Interventions
Investigational drug, Irinotecan, 5-fluorouracil, Leucovorin
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
28
States / cities
Little Rock, Arkansas • Anaheim, California • Concord, California + 24 more
Conditions
Primary Progressive Multiple Sclerosis
Interventions
Placebo, Laquinimod
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Phoenix, Arizona • Newport Beach, California • San Francisco, California + 11 more
Conditions
Influenza Prevention, Pandemic Influenza Prevention
Interventions
VRC-FLUMOS0122-00-VP, ALFQ
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
Conditions
High Risk Prostate Carcinoma, Prostate Cancer
Interventions
Abiraterone acetate, Prednisone, Hyperpolarized [1-13C] pyruvate (HP 13C), Magnetic Resonance Imaging (MRI), Non-investigational radical prostatectomy (RP), Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT)
Drug · Procedure
Lead sponsor
Ivan de Kouchkovsky, MD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
San Francisco, California
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, PF-04937319 - 3mg, PF-04937319 - 20mg, PF-04937319 - 50mg, PF-04937319 - 100mg, Sitagliptin - 100mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
24
States / cities
Anaheim, California • Los Angeles, California • Spring Valley, California + 18 more
Conditions
Ductal Carcinoma in Situ
Interventions
Tamoxifen, Exemestane, Letrozole, Anastrazole, Testosterone + Anastrazole, Elacestrant, Z-endoxifen
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
28
States / cities
Berkeley, California • Duarte, California • Irvine, California + 21 more
Conditions
Solid Tumors
Interventions
TAK-593
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Analgesia, Obstetrical, Postpartum Hemorrhage, Opioid Use, Nonsteroidals (NSAIDs)Toxicity, Coagulation Defect; Postpartum, Postoperative Pain, Ketorolac Adverse Reaction, Blood Loss, Postoperative
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg, Glimepiride
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Roseville, California • San Diego, California • Walnut Creek, California + 17 more
Conditions
Solid Tumor
Interventions
Bevacizumab, Cyclophosphamide, Valproic Acid, Temsirolimus
Drug
Lead sponsor
Miller Children's & Women's Hospital Long Beach
Other
Eligibility
12 Months to 31 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
2
States / cities
Long Beach, California • Orange, California
Conditions
Idiopathic Hypersomnia
Interventions
Serdexmethylphenidate, Placebo
Drug · Other
Lead sponsor
Zevra Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
41
States / cities
Birmingham, Alabama • Daphne, Alabama • Guntersville, Alabama + 34 more
Conditions
Carcinoma
Interventions
Everolimus, Everolimus Placebo, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Fayetteville, Arkansas • Fountain Valley, California • La Jolla, California + 15 more
Conditions
Diabetes Type 2, Periodontal Disease, Caries
Interventions
Diabetes Oral Health Program, Stannous Fluoride Dentifrice, Cetylpyridinium Chloride (CPC) and Zinc Lactate Mouthwash
Behavioral · Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Long Island City, New York
Conditions
Photosensitive Epilepsy
Interventions
Fenfluramine Hydrochloride
Drug
Lead sponsor
Elizabeth Anne Thiele
Other
Eligibility
4 Years to 25 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Lymphoma,Non-Hodgkin, Lymphoma, Hodgkin, Lymphoma, Follicular, Marginal Zone Lymphoma, Large Cell Lymphoma, Mantle-Cell Lymphoma, Gray Zone Lymphoma, Burkitt Lymphoma, High Risk Undifferentiated Acute Leukemia
Interventions
Bendamustine, Cyclophosphamide
Drug
Lead sponsor
University of Arizona
Other
Eligibility
4 Years to 30 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Tucson, Arizona